

## Correspondence

Psychological Medicine, 40 (2010).  
doi:10.1017/S0033291710000012

### Letter to the Editor

#### Further evidence is required to confirm association between *CACNA1C* gene variants and bipolar affective disorder

In their invited review on the genetics of bipolar affective disorder (BP), Keers *et al.* (2009) reported multiple association signals across the *CACNA1C* gene and suggested that because ‘these association signals were located in three blocks of largely distinct regions of linkage disequilibrium (LD)’ they ‘may therefore be considered as three relatively independent associations between *CACNA1C* and BP’.

However, it should be noted that non-negligible LD often exists between non-contiguous single nucleotide polymorphisms (SNPs), separated by tens to sometimes hundreds of kilobases and within separate so-called ‘LD blocks’, and that in the specific case reported by Keers *et al.*, the moderate associations ( $7.38 \times 10^{-5} \leq p \leq 3.88 \times 10^{-4}$ ) between 15 SNPs and BP across *CACNA1C* can be completely explained by a single effect.

As shown in Fig. 1, substantial LD ( $r^2$ ) (calculated using release 22 HapMapI+II CEU data; <http://www.hapmap.org>) exists between the 15 SNPs listed in table 1 of Keers *et al.* (2009), thus indicating that these SNPs are expected to provide similar evidence for association. Indeed, this can be easily demonstrated through simulating the results of Keers *et al.* by splitting the HapMap CEU samples into two groups to approximate the evidence for association ( $p \cong 7 \times 10^{-5}$ ) of the most significant SNP (rs2238054) reported by Keers *et al.* and performing association analysis with and without conditioning on rs2238054.

Results from allelic association analyses utilizing logistic regression within the PLINK program (Purcell *et al.* 2007) (Table 1), clearly demonstrate that after conditioning on rs2238054, none of the 14 remaining SNPs listed in table 1 of Keers *et al.* show evidence for association.

As a consequence, while the reported association(s) between *CACNA1C* and BP remain an interesting, although non-genome-wide significant finding, there is currently no evidence for multiple independent effects and further studies are therefore required to confirm involvement of *CACNA1C* variants with BP susceptibility.

### Declaration of Interest

None.

### References

- Keers R, Farmer AE, Aitchison KJ (2009). Extracting a needle from a haystack: reanalysis of whole genome data reveals a readily translatable finding. *Psychological Medicine* 39, 1231–1235.
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW, Daly MJ, Sham PC (2007). PLINK: a toolset for whole-genome association and population-based linkage analysis. *American Journal of Human Genetics* 81, 559–575.

DALE R. NYHOLT  
Neurogenetics Laboratory,  
Queensland Institute of Medical Research,  
Queensland, Australia  
(Email: Dale.Nyholt@qimr.edu.au)

### The authors reply

We welcome Dr Nyholt’s further analyses of our findings from the WTCCC data and any further discussion regarding this important candidate for bipolar disorder (BP). We agree that Dr Nyholt’s analysis suggests that the association signals we detected between variants in the *CACNA1C* and BP may not be entirely independent. This should not, however, detract from the body of evidence now linking *CACNA1C* with BD or from the focus in our original article, that this candidate also represents a potential drug target (Keers *et al.* 2009).

In addition to the positive findings reported by Sklar *et al.* (2002, 2008), a large collaborative study combining data from three genome-wide association datasets identified a genome-wide significant association signal in *CACNA1C* (Ferreira *et al.* 2008). The top hit from this study has subsequently been associated with schizophrenia and major depression (Green *et al.* 2009) and, consistent with previous studies of both disorders and BP, shown to confer specific verbal fluency deficits in a population sample (Krug *et al.* 2009).


*CACNA1C* encodes the alpha subunit of the calcium channel Ca<sub>v</sub>1.2. The association between calcium dysregulation and BP is well documented (Warsh *et al.* 2004), as is the overlap between BP and other ‘channelopathies’ such as migraine and epilepsy (Sheftell & Atlas, 2002). Moreover, drugs which affect

**Table 1.** Simulated unconditional and conditional association results for the 15 CACNA1C SNPs listed in table 1 of Keers *et al.* (2009)

CHR	SNP	Position (bp)	Allele	Unconditional results			Conditioned on rs2238054 <sup>a</sup>		
				OR	Stat	<i>p</i>	OR	Stat	<i>p</i>
12	rs10848628	2182750	C	6.61	3.93	$8.44 \times 10^{-5}$	N.A.	N.A.	N.A.
12	rs12422554	2182881	C	5.57	3.92	$8.93 \times 10^{-5}$	N.A.	N.A.	N.A.
12	rs4765902	2183226	A	5.57	3.92	$8.93 \times 10^{-5}$	N.A.	N.A.	N.A.
12	rs10848632	2186254	T	5.35	3.77	$1.65 \times 10^{-4}$	$4.31 \times 10^{-9}$	$-7.90 \times 10^{-4}$	1.00
12	rs10848633	2186280	G	5.33	3.78	$1.56 \times 10^{-4}$	$4.38 \times 10^{-9}$	$-7.90 \times 10^{-4}$	1.00
12	rs10848634	2186388	C	5.40	3.84	$1.21 \times 10^{-4}$	N.A.	N.A.	N.A.
12	rs10848635	2186456	A	5.25	3.76	$1.71 \times 10^{-4}$	N.A.	N.A.	N.A.
12	rs10848636	2186754	T	5.57	3.92	$8.93 \times 10^{-5}$	N.A.	N.A.	N.A.
12	rs11062156	2187784	A	5.60	3.92	$8.90 \times 10^{-5}$	N.A.	N.A.	N.A.
12	rs2238054 <sup>a</sup>	2187905	C	5.57	3.92	$8.93 \times 10^{-5}$	N.A.	N.A.	N.A.
12	rs1006737	2215556	A	4.15	3.57	$3.55 \times 10^{-4}$	1.89	1.24	0.22
12	rs4765905	2219845	C	4.14	3.60	$3.24 \times 10^{-4}$	1.90	1.24	0.21
12	rs10744560	2257360	T	4.27	3.67	$2.41 \times 10^{-4}$	1.92	1.26	0.21
12	rs4765914	2290638	T	2.89	2.58	$9.95 \times 10^{-3}$	1.00	$-3.84 \times 10^{-3}$	1.00
12	rs10774037	2290787	G	2.92	2.66	$7.89 \times 10^{-3}$	1.10	0.20	0.84

OR, Odds ratio; Stat, *t* statistic; N.A. indicates rs2238054 completely accounted for the association signal at this locus.

<sup>a</sup> SNP rs2238054 produced the most significant association signal in Keers *et al.* (2009).



**Fig. 1.** Linkage disequilibrium ( $r^2$ ) plot showing high correlation among the 15 SNPs listed in Table 1 of Keers *et al.* (2009); where white cells represent  $r^2 = 0$ , shades of grey represent  $0 < r^2 < 1$ , and black cells represent  $r^2 = 1$ .

interneuronal calcium ion activity by targeting  $Ca_v1.2$  have been shown to be effective in the treatment of BP (Levy & Janicak, 2000).

CACNA1C remains a biologically plausible drug target associated with BP. More in-depth genetic and pharmacogenetic studies of CACNA1C and BP may yet provide a greater understanding of the aetiology and treatment of the disorder.

## References

- Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, Fan J, Kirov G, Perlis RH, Green EK, Smoller JW, Grozeva D, Stone J, Nikolov I, Chambert K, Hamshere ML, Nimgaonkar VL, Moskvina V, Thase ME, Caesar S, Sachs GS, Franklin J, Gordon-Smith K, Ardlie KG, Gabriel SB, Fraser C, Blumenstiel B, Defelice M, Breen G, Gill M, Morris DW, Elkin A, Muir WJ, McGhee KA, Williamson R, MacIntyre DJ, MacLean AW, St Clair D, Robinson M, Van Beck M, Pereira AC, Kandaswamy R, McQuillin A, Collier DA, Bass NJ, Young AH, Lawrence J, Ferrier IN, Anjorin A, Farmer A, Curtis D, Scolnick EM, McGuffin P, Daly MJ, Corvin AP, Holmans PA, Blackwood DH, Gurling HM, Owen MJ, Purcell SM, Sklar P, Craddock N (2008). Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. *Nature Genetics* **40**, 1056–1058.
- Green EK, Grozeva D, Jones I, Jones L, Kirov G, Caesar S, Gordon-Smith K, Fraser C, Forty L, Russell E, Hamshere ML, Moskvina V, Nikolov I, Farmer A, McGuffin P, Holmans PA, Owen MJ, O'Donovan MC, Craddock N (2009). The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. *Molecular Psychiatry*. Published online: 21 July 2009. doi: 10.1038/mp.2009.49.
- Keers R, Farmer AE, Aitchison KJ (2009). Extracting a needle from a haystack: reanalysis of whole genome data reveals a readily translatable finding. *Psychological Medicine* **39**, 1231–1235.
- Krug A, Nieratschker V, Markov V, Krach S, Jansen A, Zerres K, Eggermann T, Stocker T, Shah NJ, Treutlein J, Muhleisen TW, Kircher T (2009). Effect of CACNA1C rs1006737 on neural correlates of verbal fluency in healthy individuals. *Neuroimage* **49**, 1831–1836.
- Levy NA, Janicak PG (2000). Calcium channel antagonists for the treatment of bipolar disorder. *Bipolar Disorders* **2**, 108–119.
- Sheftell FD, Atlas SJ (2002). Migraine and psychiatric comorbidity: From theory and hypotheses to clinical application. *Headache* **42**, 934–944.
- Sklar P, Gabriel SB, McClinnis MG, Bennett P, Lim YM, Tsan G, Schaffner S, Kirov G, Jones I, Owen M, Craddock N, DePaulo JR, Lander ES (2002). Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. *Molecular Psychiatry* **7**, 579–593.
- Sklar P, Smoller JW, Fan J, Ferreira MAR, Perlis RH, Chambert K, Nimgaonkar VL, McQueen MB, Faraone SV, Kirby A, de Bakker PIW, Ogdie MN, Thase ME, Sachs GS, Todd-Brown K, Gabriel SB, Sougnez C, Gates C, Blumenstiel B, Defelice M, Ardlie KG, Franklin J, Muir WJ, McGhee KA, MacIntyre DJ, McLean A, VanBeck M, McQuillin A, Bass NJ, Robinson M, Lawrence J, Anjorin A, Curtis D, Scolnick EM, Daly MJ, Blackwood DH, Gurling HM, Purcell SM (2008). Whole-genome association study of bipolar disorder. *Molecular Psychiatry* **13**, 558–569.
- Warsh JJ, Andreopoulos S, Lia PP (2004). Role of intracellular calcium signalling in the pathophysiology and pharmacotherapy of bipolar disorder: current status. *Clinical Neuroscience Research* **4**, 201–213.

ROBERT KEERS, ANNE E. FARMER,  
KATHERINE J. AITCHISON  
MRC SGDP Centre, Institute of Psychiatry at King's  
College London, London, UK  
(Email: Robert.keers@iop.kcl.ac.uk)